Canakinumab in Patients With COVID-19 and Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

October 23, 2020

Primary Completion Date

August 17, 2021

Study Completion Date

August 17, 2021

Conditions
Coronavirus InfectionDiabetes Mellitus, Type 2
Interventions
DRUG

Canakinumab

Body weight adjusted dose in 250 ml 5% dextrose solution i.v. over 2 hours

DRUG

Placebo

Aqua ad injectabilia in 250 ml 5% dextrose solution i.v. over 2 hours

Trial Locations (9)

1011

University Hospital Lausanne, Lausanne

1205

University Hospital Geneva, Geneva

2800

Hopital du Jura, Delémont

3010

University Hospital Bern, Bern

4031

University Hospital Basel, Basel

5001

University Medical Clinic Aarau, Aarau

6004

Cantonal Hospital Lucerne, Lucerne

8091

University Hospital Zürich, Zurich

9001

Cantonal Hospital St Gallen, Sankt Gallen

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Swiss National Science Foundation

OTHER

lead

University Hospital, Basel, Switzerland

OTHER